Johnson & Johnson’s seltorexant is one of two new therapies that the company reckons could become blockbuster treatments for depression, and data from a phase 3 trial
Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD) from Numab Therapeutics in an all-cash deal valued at $1.25 bill
Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority revi
In this instalment of our renewed clinical trials round-ups, we look at life sciences research and development announced during the week of 20th to 24th May, from early-stage onwards.
Johnson & Johnson has agreed a $850 million deal to acquire Proteologix that will give it a pair of early-stage bispecific antibodies with immunology applications, inc
In another setback for the pharma industry, a US federal judge has rejected a bid to overturn the Medicare pricing negotiation brought by Bristol-Myers Squibb and Johnson